Oric Pharmaceuticals, Inc. (ORIC) shareholders
ORICNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.86−0.64 (-7.53%)
Close on Nov 13, 2026Market cap $814.71MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
124M of 104M shares
Institutional holders
181
31 new, 30 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
0 buys · 16 sales
Net sold $2.96M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Ott David C. Joint filing with Viking Global Opportunities Parent GP LLC (9.99%), Halvorsen Ole Andreas (9.99%) and 5 more | 8,729,345 | 9.99% | 13G (passive) amendment | Jun 30, 2025 |
| Viking Global Investors LP Joint filing with Viking Global Opportunities Parent GP LLC (7.80%), Halvorsen Ole Andreas (7.80%) and 4 more | 8,264,607 | 7.80% | 13G (passive) amendment | Mar 31, 2026 |
| Rocco Sgobbo Joint filing with Nextech Crossover I GP S.a. r.l. (8.40%), Nextech Crossover I SCSp (8.40%) and 2 more | 7,162,637 | 8.40% | 13G (passive) amendment | Jun 30, 2025 |
| EcoR1 Capital, LLC Joint filing with Oleg Nodelman (6.90%), EcoR1 Capital Fund Qualified, L.P. (6.50%) | 6,728,116 | 6.90% | 13G (passive) | Jul 29, 2025 |
| Venrock Healthcare Capital Partners III, L.P. Joint filing with VHCP Co-Investment Holdings III, LLC (7.70%), Venrock Healthcare Capital Partners EG, L.P. (7.70%) and 4 more | 6,596,885 | 7.70% | 13G (passive) | Apr 8, 2025 |
| Viking Global Opportunities Parent GP LLC Joint filing with Halvorsen Ole Andreas (9.20%), Ott David C. (9.20%) and 5 more | 6,572,700 | 9.20% | 13G (passive) amendment | Mar 31, 2025 |
| Bong Y. Koh Joint filing with Venrock Healthcare Capital Partners III, L.P. (5.80%), VHCP Co-Investment Holdings III, LLC (5.80%) and 4 more | 5,676,230 | 5.80% | 13G (passive) amendment | Dec 31, 2025 |
| BlackRock, Inc. | 5,473,145 | 5.60% | 13G (passive) | Dec 31, 2025 |
| T. Rowe Price Associates, Inc. | 5,387,783 | 5.40% | 13G (passive) | Mar 31, 2026 |
| Simeon George Joint filing with SR One Capital Management, LLC (5.40%) | 4,615,384 | 5.40% | 13D (active) | May 29, 2025 |
| Steven A. Cohen Joint filing with Point72 Asset Management, L.P. (5.10%), Point72 Capital Advisors, Inc. (5.10%) | 4,401,659 | 5.10% | 13G (passive) | May 29, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ORIC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Nextech Invest, Ltd. | 7,162,637 | 6.91% | $77.57M | – | 3.68% |
| BlackRock, Inc. | 6,823,973 | 6.58% | $73.90M | +839,421 | 0.00% |
| EcoR1 Capital, LLC | 6,728,116 | 6.49% | $72.87M | – | 3.54% |
| Price T Rowe Associates Inc /Md/ | 6,617,554 | 6.38% | $71.67M | +1,229,771 | 0.01% |
| Viking Global Investors LP | 5,126,762 | 4.95% | $55.52M | −697,771 | 0.16% |
| State Street Corp | 4,894,000 | 4.72% | $53.00M | +1,191,804 | 0.00% |
| Sr One Capital Management, LP | 4,615,384 | 4.45% | $49.98M | +100,455 | 4.81% |
| VR Adviser, LLC | 4,319,765 | 4.17% | $46.78M | – | 1.42% |
| NEA Management Company, LLC | 4,118,621 | 3.97% | $44.60M | – | 2.81% |
| Vanguard Capital Management LLC | 3,951,169 | 3.81% | $42.79M | +264,162 | 0.00% |
| AIHC Capital Management Ltd | 3,828,460 | 3.69% | $41.46M | +1,368,909 | 39.77% |
| Alkeon Capital Management LLC | 3,739,096 | 3.61% | $40.49M | −765,000 | 0.05% |
| Column Group LLC | 3,540,777 | 3.42% | $38.35M | – | 43.53% |
| Siren, L.L.C. | 2,998,192 | 2.89% | $32.47M | – | 0.66% |
| FMR LLC | 2,635,475 | 2.54% | $28.54M | +201,395 | 0.00% |
| Citadel Advisors LLC | 2,595,299 | 2.50% | $28.11M | +172,558 | 0.00% |
| Goldman Sachs Group Inc | 2,451,796 | 2.37% | $26.55M | +976,084 | 0.00% |
| Geode Capital Management, LLC | 2,090,089 | 2.02% | $22.64M | +251,288 | 0.00% |
| First Turn Management, LLC | 2,017,284 | 1.95% | $21.85M | – | 2.34% |
| Orbimed Advisors LLC | 2,015,000 | 1.94% | $21.82M | −678,929 | 0.40% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 181 | 124M | 100.0% | 31 / 82 | 42 / 30 | 18M | 14M |
| Q1 2026 | 182 | 119M | 100.0% | 40 / 57 | 64 / 22 | 20M | 16M |
| Q4 2025 | 165 | 120M | 100.0% | 35 / 68 | 34 / 21 | 19M | 8M |
| Q3 2025 | 152 | 108M | 100.0% | 32 / 59 | 33 / 22 | 19M | 5M |
| Q2 2025 | 142 | 93M | 90.2% | 35 / 43 | 51 / 35 | 27M | 12M |
| Q1 2025 | 143 | 79M | 76.4% | 33 / 50 | 38 / 17 | 17M | 8M |
| Q4 2024 | 129 | 76M | 73.1% | 27 / 51 | 26 / 20 | 11M | 5M |
| Q3 2024 | 122 | 70M | 67.4% | 24 / 38 | 39 / 13 | 11M | 3M |
| Q2 2024 | 113 | 68M | 65.3% | 22 / 54 | 19 / 20 | 6M | 3M |
| Q1 2024 | 112 | 65M | 62.3% | 35 / 32 | 28 / 15 | 20M | 7M |
| Q4 2023 | 92 | 51M | 49.4% | 20 / 36 | 21 / 17 | 8M | 6M |
| Q3 2023 | 90 | 49M | 47.3% | 16 / 27 | 28 / 9 | 6M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
193 funds held ORIC in Q2 2026, 50% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ORIC | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3,265,284 | 3.15% | $35.36M | 0.33% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,918,973 | 2.82% | $31.61M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,947,237 | 1.88% | $21.09M | 0.03% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,533,122 | 1.48% | $16.60M | 0.14% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 1,261,301 | 1.22% | $13.66M | 0.14% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,114,736 | 1.08% | $12.07M | 0.08% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 951,433 | 0.92% | $10.30M | 0.58% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 942,755 | 0.91% | $10.21M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 817,877 | 0.79% | $9.05M | 0.03% | Jul 31, 2026 |
| Fidelity Growth Company Fund | 718,374 | 0.69% | $6.07M | 0.01% | May 31, 2026 |
| Franklin Biotechnology Discovery Fund | 659,005 | 0.64% | $7.30M | 0.63% | Jul 31, 2026 |
| Vanguard Explorer Fund | 526,858 | 0.51% | $5.83M | 0.03% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 483,278 | 0.47% | $5.23M | 0.04% | Jun 30, 2026 |
| iShares Biotechnology ETF | 430,714 | 0.42% | $4.66M | 0.05% | Jun 30, 2026 |
| U.S. Small Cap Portfolio | 403,961 | 0.39% | $4.47M | 0.02% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jacob Chacko | PRESIDENT AND CEO, Director | 581,711 | 0.56% | Jan 6, 2026 |
| Dominic Piscitelli | Chief Financial Officer | 69,828 | 0.07% | Oct 21, 2026 |
| Pratik S. Multani | Chief Medical Officer | 68,149 | 0.07% | Jan 6, 2026 |
| Richard A. Heyman | Director | 241,772 | 0.23% | Oct 2, 2026 |
| Mardi Dier | Director | 0 | – | Jan 6, 2026 |
| Steven L. Hoerter | Director | – | – | Jan 6, 2026 |
| Lori Anne Kunkel | Director | 84,200 | 0.08% | Jan 6, 2026 |
| Angie You | Director | 28,000 | 0.03% | Jan 6, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dominic Piscitelli Chief Financial Officer | Oct 20, 2026 | Sale(10b5-1 plan) | −14,000 | $13.53 | $189.39K | 69,828 |
| Dominic Piscitelli Chief Financial Officer | Oct 20, 2026 | Option exercise | +14,000 | $4.36 | $61.04K | 83,828 |
| Richard A. Heyman Director | Oct 1, 2026 | Sale(10b5-1 plan) | −3,200 | $12.91 | $41.33K | 203,472 |
| Richard A. Heyman Director | Oct 1, 2026 | Sale(10b5-1 plan) | −3,500 | $12.91 | $45.20K | 38,300 |
| Richard A. Heyman Director | Oct 1, 2026 | Option exercise | +3,500 | $1.60 | $5.60K | 41,800 |
| Dominic Piscitelli Chief Financial Officer | Sep 28, 2026 | Option exercise | +13,400 | $4.36 | $58.42K | 83,228 |
| Dominic Piscitelli Chief Financial Officer | Sep 28, 2026 | Sale(10b5-1 plan) | −13,400 | $13.53 | $181.30K | 69,828 |
| Dominic Piscitelli Chief Financial Officer | Sep 24, 2026 | Sale(10b5-1 plan) | −500 | $13.51 | $6.76K | 69,828 |
| Dominic Piscitelli Chief Financial Officer | Sep 24, 2026 | Sale(10b5-1 plan) | −100 | $13.50 | $1.35K | 70,328 |
| Dominic Piscitelli Chief Financial Officer | Sep 24, 2026 | Option exercise | +600 | $4.36 | $2.62K | 70,428 |
| Dominic Piscitelli Chief Financial Officer | Aug 26, 2026 | Sale(10b5-1 plan) | −77,000 | $13.69 | $1.05M | 69,828 |
| Dominic Piscitelli Chief Financial Officer | Aug 26, 2026 | Option exercise | +25,000 | $6.00 | $150.00K | 146,828 |
| Dominic Piscitelli Chief Financial Officer | Aug 26, 2026 | Option exercise | +52,000 | $4.36 | $226.72K | 121,828 |
| Richard A. Heyman Director | Jul 24, 2026 | Sale(10b5-1 plan) | −6,100 | $12.02 | $73.32K | 206,672 |
| Richard A. Heyman Director | Jul 24, 2026 | Sale(10b5-1 plan) | −7,000 | $12.02 | $84.14K | 38,300 |
| Richard A. Heyman Director | Jul 24, 2026 | Option exercise | +3,500 | $1.60 | $5.60K | 45,300 |
| Richard A. Heyman Director | Jul 6, 2026 | Sale(10b5-1 plan) | −300 | $12.00 | $3.60K | 212,772 |
| Dominic Piscitelli Chief Financial Officer | Feb 24, 2026 | Option exercise | +52,000 | $4.36 | $226.72K | 120,148 |
| Dominic Piscitelli Chief Financial Officer | Feb 24, 2026 | Sale(10b5-1 plan) | −52,000 | $13.51 | $702.52K | 68,148 |
| Richard A. Heyman Director | Jan 16, 2026 | Sale(10b5-1 plan) | −3,500 | $12.00 | $42.00K | 41,800 |
| Richard A. Heyman Director | Jan 16, 2026 | Sale(10b5-1 plan) | −3,200 | $12.00 | $38.40K | 213,072 |
| Pratik S. Multani Chief Medical Officer | Dec 16, 2025 | Sale | −10,720 | $9.06 | $97.12K | 68,149 |
| Dominic Piscitelli Chief Financial Officer | Dec 16, 2025 | Sale | −10,720 | $9.06 | $97.12K | 68,148 |
| Jacob Chacko PRESIDENT AND CEO, Director | Dec 16, 2025 | Sale | −33,374 | $9.06 | $302.37K | 581,711 |
| Pratik S. Multani Chief Medical Officer | Dec 15, 2025 | Option exercise | +29,333 | – | – | 78,869 |
| Dominic Piscitelli Chief Financial Officer | Dec 15, 2025 | Option exercise | +29,333 | – | – | 78,868 |
| Jacob Chacko PRESIDENT AND CEO, Director | Dec 15, 2025 | Option exercise | +83,666 | – | – | 615,085 |
| Lori Anne Kunkel Director | Dec 8, 2025 | Option exercise | +10,000 | $7.90 | $79.00K | 84,200 |
| Lori Anne Kunkel Director | Dec 4, 2025 | Option exercise | +5,534 | $3.75 | $20.75K | 74,200 |
| Jacob Chacko PRESIDENT AND CEO, Director | Oct 6, 2025 | Sale(10b5-1 plan) | −37,461 | $12.32 | $461.52K | 531,419 |
| Dominic Piscitelli Chief Financial Officer | Oct 6, 2025 | Option exercise | +11,000 | $4.36 | $47.96K | 59,317 |
| Dominic Piscitelli Chief Financial Officer | Oct 6, 2025 | Sale(10b5-1 plan) | −11,000 | $14.52 | $159.72K | 48,317 |
| Richard A. Heyman Director | Oct 3, 2025 | Option exercise | +1,447 | $3.75 | $5.43K | 45,300 |
| Richard A. Heyman Director | Oct 3, 2025 | Option exercise | +31,353 | $1.60 | $50.16K | 43,853 |
| Jacob Chacko PRESIDENT AND CEO, Director | Oct 1, 2025 | Sale(10b5-1 plan) | −53,001 | $12.05 | $638.66K | 568,880 |
| Jacob Chacko PRESIDENT AND CEO, Director | Sep 30, 2025 | Sale(10b5-1 plan) | −34,538 | $12.01 | $414.80K | 621,881 |
| Jacob Chacko PRESIDENT AND CEO, Director | Sep 22, 2025 | Sale(10b5-1 plan) | −125,000 | $10.80 | $1.35M | 656,419 |
| Dominic Piscitelli Chief Financial Officer | Jul 1, 2025 | Sale(10b5-1 plan) | −20,000 | $10.05 | $201.00K | 48,317 |
| Dominic Piscitelli Chief Financial Officer | Jun 24, 2025 | Sale(10b5-1 plan) | −32,466 | $10.50 | $340.89K | 68,317 |
| Dominic Piscitelli Chief Financial Officer | Jun 23, 2025 | Sale(10b5-1 plan) | −450 | $10.01 | $4.50K | 100,783 |
| Dominic Piscitelli Chief Financial Officer | Jun 23, 2025 | Sale(10b5-1 plan) | −584 | $10.00 | $5.84K | 101,233 |
| Angie You Director | Jun 23, 2025 | Buy | +1,403 | $9.43 | $13.23K | 28,000 |
| Angie You Director | Jun 20, 2025 | Buy | +26,597 | $9.39 | $249.75K | 26,597 |
| Dominic Piscitelli Chief Financial Officer | Jun 12, 2025 | Sale(10b5-1 plan) | −300 | $10.00 | $3.00K | 101,817 |
| Dominic Piscitelli Chief Financial Officer | Jun 11, 2025 | Sale(10b5-1 plan) | −1,276 | $10.00 | $12.76K | 103,817 |
| Dominic Piscitelli Chief Financial Officer | Jun 11, 2025 | Sale(10b5-1 plan) | −1,700 | $10.01 | $17.02K | 102,117 |
| Dominic Piscitelli Chief Financial Officer | Jun 10, 2025 | Sale(10b5-1 plan) | −324 | $10.00 | $3.24K | 105,093 |
| Dominic Piscitelli Chief Financial Officer | Jun 9, 2025 | Sale(10b5-1 plan) | −300 | $10.00 | $3.00K | 103,864 |
| Dominic Piscitelli Chief Financial Officer | Jun 6, 2025 | Sale(10b5-1 plan) | −2,600 | $10.01 | $26.03K | 104,164 |
| Lori Anne Kunkel Director | Mar 3, 2025 | Option exercise | +27,666 | $3.75 | $103.75K | 48,166 |
| Lori Anne Kunkel Director | Mar 3, 2025 | Option exercise | +20,500 | $6.33 | $129.77K | 68,666 |
| Pratik S. Multani Chief Medical Officer | Dec 16, 2024 | Sale | −8,850 | $8.28 | $73.28K | 46,765 |
| Jacob Chacko PRESIDENT AND CEO, Director | Dec 16, 2024 | Sale | −24,660 | $8.28 | $204.18K | 778,648 |
| Dominic Piscitelli Chief Financial Officer | Dec 16, 2024 | Sale | −8,851 | $8.28 | $73.29K | 106,764 |
| Pratik S. Multani Chief Medical Officer | Dec 15, 2024 | Option exercise | +24,042 | – | – | 55,615 |
| Jacob Chacko PRESIDENT AND CEO, Director | Dec 15, 2024 | Option exercise | +67,000 | – | – | 803,308 |
| Dominic Piscitelli Chief Financial Officer | Dec 15, 2024 | Option exercise | +24,042 | – | – | 115,615 |
| Lori Anne Kunkel Director | Jun 3, 2024 | Option exercise | +20,500 | $3.75 | $76.88K | 20,500 |
| Jacob Chacko PRESIDENT AND CEO, Director | Mar 6, 2024 | Sale(10b5-1 plan) | −40,000 | $16.21 | $648.40K | 728,544 |
| Jacob Chacko PRESIDENT AND CEO, Director | Feb 7, 2024 | Sale(10b5-1 plan) | −26,042 | $12.30 | $320.32K | 768,544 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
10.95%
11M shares short
Days to cover
4.8
At 2M shares a day
Change since last report
-30.4%
From 15M shares
Short volume, 20 days
45.0%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Oric Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 205,262 shares on Sep 8, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Richard A. Heyman Director | Oct 1, 2026 | 7,600 | $102.37K | Oct 1, 2026 | Private Investment |
| Richard A. Heyman Director | Oct 1, 2026 | 8,100 | $109.11K | Oct 1, 2026 | Stock Option Exercise |
| Dominic Piscitelli Officer | Aug 26, 2026 | 229,500 | $3.10M | Aug 26, 2026 | Stock Option Exercise |
| Richard A. Heyman Director | Jul 6, 2026 | 6,400 | $76.80K | Jul 6, 2026 | Stock Option Exercise |
| Richard A. Heyman Director | Jul 6, 2026 | 7,000 | $84.00K | Jul 6, 2026 | Stock Option Exercise |
| Dominic Piscitelli Officer | Feb 24, 2026 | 52,000 | $702.00K | Feb 24, 2026 | Stock Option Exercise |
| Richard A. Heyman Director | Jan 16, 2026 | 6,400 | $76.80K | Jan 16, 2026 | Stock Option Exercise |
| Richard A. Heyman Director | Jan 16, 2026 | 7,000 | $84.00K | Jan 16, 2026 | Stock Option Exercise |
| Jacob Chacko Officer, Director | Dec 16, 2025 | 33,374 | $302.37K | Dec 16, 2025 | Restricted Stock Units |
| Pratik S. Multani Officer | Dec 16, 2025 | 10,720 | $97.13K | Dec 16, 2025 | Restricted Stock Units |
| Dominic Piscitelli Officer | Dec 16, 2025 | 10,720 | $97.13K | Dec 16, 2025 | Restricted Stock Units |
| Dominic Piscitelli Officer | Oct 6, 2025 | 50,000 | $725.00K | Oct 6, 2025 | Stock Option Exercise |
| Jacob Chacko Director, Officer | Sep 22, 2025 | 250,000 | $2.63M | Sep 22, 2025 | Open Market Purchase |
| Dominic Piscitelli Officer | Jun 6, 2025 | 60,000 | $540.00K | Jun 6, 2025 | Open Market Purchase |
| Dominic Piscitelli Officer | Dec 16, 2024 | 8,851 | $73.30K | Dec 16, 2024 | Restricted Stock Units |
See a number that looks wrong?